Carregant...
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap
Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapidly and safely bring industry sponsored pivotal trials to our patients and to prepare for a...
Guardat en:
| Publicat a: | J Immunother Cancer |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5514522/ https://ncbi.nlm.nih.gov/pubmed/28716155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0265-y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|